Novartis buys CoStim as big pharmas boost their cancer immunotherapy arsenals

Novartis has bought private US company CoStim Pharmaceuticals for an undisclosed sum in a transaction that demonstrates the increasing allure of cancer immunotherapy to big pharma as a therapeutic strategy.